Organization
Interdisciplinary Study Center with ECTU, Medical Clinic and Polyclinic II of the University Hospital
2 abstracts
Abstract
First-in-human dose-escalation trial of BI 764532, a delta-like ligand 3 (DLL3)/CD3 IgG-like T-cell engager in patients (pts) with DLL3-positive (DLL3+) small-cell lung cancer (SCLC) and neuroendocrine carcinoma (NEC).Org: Technical University Dresden, Medical Faculty, NCT/UCC Early Clinical Trial Unit, Department of Medical Oncology, Vall d'Hebron University Hospital & Vall d'Hebron Institute of Oncology, Washington University School of Medicine, Department of Immunology and Oncology, Clínica Universidad de Navarra, Cancer Research Program, IMIM (Institut Hospital del Mar d'Investigacions Mèdiques),
Abstract
First-in-human dose-escalation trial of BI 764532, a delta-like ligand 3 (DLL3)/CD3 IgG-like T-cell engager in patients (pts) with DLL3-positive (DLL3+) small-cell lung cancer (SCLC) and neuroendocrine carcinoma (NEC).Org: Technical University Dresden, Medical Faculty, NCT/UCC Early Clinical Trial Unit, NCT/UCC Early Clinical Trial Unit, Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Barcelona, Spain, Vall d'Hebron Institute of Oncology,